Magazine Article | February 1, 2019

Foreign Investors Trigger ‘Critical Technology' Review for Biotech

Source: Life Science Leader

By Gail Dutton, Contributing Writer
Follow Me On Twitter @GailLdutton

U.S. biotech companies that receive foreign investments and are developing critical technologies or the components that enable those technologies now might have to file mandatory declarations with the Committee on Foreign Investment in the U.S. (CFIUS). The new rules apply to investors from any foreign country — and apply even if the investor does not take a controlling interest in the company.